Key result
Catheter-directed thrombolysis was associated with lower 30-day mortality compared to systemic anticoagulation for submassive pulmonary embolism (OR 0.27; 95% CI 0.11-0.67).
Why the study?
The optimal therapy for submassive pulmonary embolism remains in question.
Does Catheter-Directed Thrombolysis reduce mortality in patients with submassive pulmonary embolism compared to Systemic Anticoagulation?
Population
Patients with submassive pulmonary embolism across six studies
Comparison
Catheter-directed thrombolysis vs systemic anticoagulation
Design
Meta-analysis
Follow-up
Up to one-year
Loading...
May support catheter-directed thrombolysis in submassive PE; extends observational data but requires randomized confirmation.
Meta-Analysis
Does Catheter-Directed Thrombolysis reduce mortality in patients with submassive pulmonary embolism compared to Systemic Anticoagulation?
Odds Ratio: 0.27 (95% CI 0.11–0.67)
Catheter-directed thrombolysis is associated with lower 30-day and 1-year mortality compared to systemic anticoagulation in submassive pulmonary embolism, without a significant increase in major bleeding.
A 2021 study conducted a meta-analysis in Submassive pulmonary embolism. Catheter-Directed Thrombolysis (CDT) vs. Systemic Anticoagulation (SA) was evaluated on 30-day mortality (OR 0.27, 95% CI 0.11-0.67). Catheter-directed thrombolysis was associated with lower 30-day mortality compared to systemic anticoagulation for submassive pulmonary embolism (OR 0.27; 95% CI 0.11-0.67).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: